JSPRW Jasper Therapeutics, Inc.
Price Chart
Executive Summary
Jasper Therapeutics received a Nasdaq deficiency notice on June 3, 2026, because its common stock bid price closed below $1.00 for 30 consecutive business days, violating Listing Rule 5550(a)(2). The company has until November 30, 2026 to regain compliance by closing at $1.00 or higher for 10 consecutive days, or it may seek a second 180-day cure period. Failure to cure could lead to delisting, which would severely reduce institutional ownership and liquidity for both JSPR and JSPRW.
Actionable Insight
Monitor for any reverse stock split announcement or capital raise as the company works toward the November 30 deadline. If the stock fails to recover above $1.00, delisting risk increases significantly, which could trigger further selling pressure in both JSPR and JSPRW warrants.
Key Facts
- Nasdaq notice received June 3, 2026 for bid price below $1.00 for 30 consecutive business days
- Initial compliance period ends November 30, 2026 (180 calendar days)
- To regain compliance, bid price must close at $1.00 or more for 10 consecutive business days
- If not cured by Nov 30, company may be eligible for an additional 180-day period if it meets other listing standards
- Company may consider a reverse stock split to cure the deficiency
- Both JSPR common stock and JSPRW warrants continue trading on Nasdaq Capital Market for now
Financial Impact
Delisting risk for a pre-revenue biotech with $0 market cap — loss of Nasdaq listing would severely impair liquidity and institutional access
Risk Factors
- Failure to regain compliance by November 30, 2026 could lead to delisting
- Even if eligible for a second 180-day period, Nasdaq staff may deny continued listing
- Reverse stock split could be necessary but may not stabilize the stock price
- Delisting would severely reduce liquidity and institutional ownership
Market Snapshot
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-066782 |
| Document: 0001213900-26-066782-index-headers.html | 0001213900-26-066782 |
| Document: 0001213900-26-066782-index.html | 0001213900-26-066782 |
| Document: 0001213900-26-066782.txt | 0001213900-26-066782 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 9, 2026
1d ago
|
8-K
| — | awaiting T+5 | — | — |
|
Jun 1, 2026
9d ago
|
8-K
| $0.0204 $0.0204 | · 0.00% | ▼ −2.75% | $0.0134 (+34.31%) |
|
May 21, 2026
20d ago
|
8-K
| $0.0204 $0.0204 | · 0.00% | ▼ −1.66% | $0.0134 (−34.31%) |
|
May 14, 2026
27d ago
|
8-K
| $0.0204 $0.0204 | · 0.00% | ▲ +0.96% | $0.0134 (+34.31%) |
|
Mar 30, 2026
10w ago
|
8-K
| $0.0204 $0.0204 | · 0.00% | ▼ −3.94% | $0.0134 (−34.31%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access